Higher plasma CXCL12 levels predict incident myocardial infarction and death in chronic kidney disease: findings from the Chronic Renal Insufficiency Cohort study

• Published in: European heart journal Vol. 35; no. 31; pp. 2115 - 2122
• Main Authors: Mehta, Nehal N, Matthews, Gregory J, Krishnamoorthy, Parasuram, Shah, Rhia, McLaughlin, Catherine, Patel, Parth, Budoff, Matthew, Chen, Jing, Wolman, Melanie, Go, Alan, He, Jiang, Kanetsky, Peter A, Master, Stephen R, Rader, Daniel J, Raj, Dominic, Gadegbeku, Crystal A, Shah, Rachana, Schreiber, Marty, Fischer, Michael J, Townsend, Raymond R, Kusek, John, Feldman, Harold I, Foulkes, Andrea S, Reilly, Muredach P
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 14.08.2014
• Subjects: Adult; Aged; Biomarkers - metabolism; Chemokine CXCL12 - metabolism; Clinical Research; Cross-Sectional Studies; Female; Humans; Incidental Findings; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction - complications; Myocardial Infarction - diagnosis; Prognosis; Prospective Studies; Renal Insufficiency, Chronic - complications; Renal Insufficiency, Chronic - mortality; Young Adult; Myocardial infarction; CXCL12; Chemokines; Atherosclerosis
• ISSN: 0195-668X; 1522-9645
• DOI: 10.1093/eurheartj/eht481

Genome-wide association studies revealed an association between a locus at 10q11, downstream from CXCL12, and myocardial infarction (MI). However, the relationship among plasma CXCL12, cardiovascular disease (CVD) risk factors, incident MI, and death is unknown. We analysed study-entry plasma CXCL12 levels in 3687 participants of the Chronic Renal Insufficiency Cohort (CRIC) Study, a prospective study of cardiovascular and kidney outcomes in chronic kidney disease (CKD) patients. Mean follow-up was 6 years for incident MI or death. Plasma CXCL12 levels were positively associated with several cardiovascular risk factors (age, hypertension, diabetes, hypercholesterolaemia), lower estimated glomerular filtration rate (eGFR), and higher inflammatory cytokine levels (P < 0.05). In fully adjusted models, higher study-entry CXCL12 was associated with increased odds of prevalent CVD (OR 1.23; 95% confidence interval 1.14, 1.33, P < 0.001) for one standard deviation (SD) increase in CXCL12. Similarly, one SD higher CXCL12 increased the hazard of incident MI (1.26; 1.09,1.45, P < 0.001), death (1.20; 1.09,1.33, P < 0.001), and combined MI/death (1.23; 1.13-1.34, P < 0.001) adjusting for demographic factors, known CVD risk factors, and inflammatory markers and remained significant for MI (1.19; 1.03,1.39, P = 0.01) and the combined MI/death (1.13; 1.03,1.24, P = 0.01) after further controlling for eGFR and urinary albumin:creatinine ratio. In CKD, higher plasma CXCL12 was associated with CVD risk factors and prevalent CVD as well as the hazard of incident MI and death. Further studies are required to establish if plasma CXCL12 reflect causal actions at the vessel wall and is a tool for genomic and therapeutic trials.